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ApoCell, on day -1 of transplantation (Mevorach et al. BBMT
2014).
We now report the summary of biomarkers measurement
(ELISA) as a correlation to the clinical grading. These include
serum levels of Il-1b, IL-2RA, IL-6, IL-7, IL-8, IL-15, TNF-R1,
and HGF (hepatic growth factor). We further report the
ApoCell clearance following the infusion, using short tandem
repeats (str) and the tolerogenic effect of ApoCell on imma-
ture dendritic cells (iDC) exposed to maturation stimuli. In
addition, a 1 year follow-up and a clinical comparison to
matched historical controls were evaluated.
The results show an excellent correlation between bio-
markers to clinical grading with a distinctive pattern be-
tween high-grade (III-IV) to low grade GVHD. A rapid
clearance of the infused ApoCell that disappears from cir-
culation within few hours and ApoCell dose-dependent tol-
erogenic effect on iDC (p<0.001) were observed. The 1 year
overall survival rate was 62% with a non-relapse survival rate
of 89% (100% for the two higher cohorts), and a signiﬁcant
(p<0.05) lower occurrence (23% in total and 0% in the two
higher dosages) of high-grade GVHD (II-IV) in comparison to
historical controls.
These results suggest that single-infusion high-dose
donor early apoptotic cells in HLA-matched myeloablative
alloBMT may be a safe and effective prophylaxis for acute
GVHD (clinicaltrials.gov no. NCT00524784).495
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Background: Sex-mismatched hematopoietic cell trans-
plantation (HCT) is associated with increased graft-versus-
host disease (GVHD) and inferior survival for almost every
conditioning regimen studied to date. The increased risk is
clearest for male recipients with female donors (F->M). We
hypothesized that total lymphoid irradiation with anti-
thymocyte globulin (TLI-ATG) could reduce adverse effects of
sex-mismatched transplant without reducing graft-versus
leukemia (GVL) effect.
Patients and Methods: We reviewed 1041 adult recipients
between 2006 and 2013 at Stanford and Karolinska Univer-
sity Hospitals, and assessed impacts of sex-mismatch within
each conditioning: TLI-ATG, other reduced-intensity condi-
tioning (RIC) and myeloablative conditioning (MAC). We also
measured allo-antibodies (HY-Ab) against 5 HY-antigens
encoded on the Y-chromosome (DBY, UTY, ZFY, EIF1AY, and
RPS4Y) at 3 months (3m) post F->M HCT in the Stanford
cohort.
Results: Within the TLI-ATG group, F->M transplant did
not associate with an increased incidence of acute or
chronic GVHD nor an increase in non-relapse mortality
(NRM). For the MAC group, F->M transplant was associated
with increased chronic GVHD (HR 1.83, P<0.01) and NRM
(HR 1.84, P¼0.022). For the RIC group F->M transplant
was associated with increased acute GVHD (HR 1.96,
P<0.01) but there was no associationwith NRM. Within the
TLI-ATG group, sex-mismatched transplant was signiﬁcantlyatch in the TLI-ATG (left), RIC (middle), and MAC (right) groups
Figure 2. HY-Ab 3m post-HCT & disease replace in F/M HCT with TLI-ATG
(MDS and CLL were not included).
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in M->F, P<0.01 in each), while no impact of sex-mismatch
on relapse was observed in the MAC or RIC groups (Fig 1).
Finally, in the TLI-ATG group, sex-mismatched transplant
was signiﬁcantly associated with superior OS (HR 0.69 in F-
>M, P¼0.037; HR 0.61 in M->F, P¼0.014), while F->M
transplant was signiﬁcantly associatedwith inferior OS in the
MAC group (HR 1.59, P¼0.018) and no improvement in OS in
the RIC group (HR 1.31, P¼0.36) (Fig 2).
In the TLI-ATG group, the beneﬁt of sex-mismatched HCT
on OS seems due to the reduced relapse rate. We previously
reported HY-Ab response post-HCT was associated with
chronic GVHD as a representative of allo-Ab response
(Nakasone et al. ASH 2013). We then hypothesized that HY-
Ab response 3m post-HCT could predict reduced relapse in F-
>MHCTwith TLI-ATG. Relapse incidence at 2 years post-HCT
was higher in the recipients who had no HY-Ab response at
3m post-HCT vs. those who did (49% vs. 26%, P¼0.037, Fig 2).
Multivariate analysis corroborated that the detection of HY-
antibodies 3m post-HCT was signiﬁcantly associated with
reduced relapse in F->M HCT with TLI-ATG [HR 0.29,
P¼0.039].
Conclusion: We conclude that the beneﬁts and risks of sex-
mismatch differ according to conditioning intensity/strategy,
and is the ﬁrst reported evidence that sex-mismatched
transplant might preferably be selected in TLI-ATG, while
avoided in MAC transplantation.496
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Acute graft versus host disease (GVHD) is a major cause of
morbidity and mortality after allogeneic hematopoietic celltransplantation (HCT). Based on established consensus
grading criteria, a correlation between clinical grading and
survival has been well established. A histologic grading sys-
tem for acute GVHD of the skin and gastrointestinal (GI) tract
has also been well established, and is routinely used by pa-
thologists when reporting this diagnosis. There are limited
data, however, on the correlation of the histologic grade with
clinical grade and its ability to predict outcome. We thus
undertook this retrospective analysis to further evaluate the
impact of histologic grade on treatment response and
outcome. Among 503 consecutive patients who underwent
allogeneic HCT from 2005-2013, we identiﬁed 234 patients
with 303 episodes where tissue biopsies (skin and GI)
conﬁrmed presence of acute GVHD. There were 140 (46%) GI
and 163 (54%) skin biopsies. Histologic grade was analyzed
and correlated with clinical grade of GVHD, day 28 treatment
response, and outcome. Although both GI and skin histology
were signiﬁcantly correlated with overall clinical grade
(p<0.001), there was a stronger association with GI histo-
logic grade (R¼0.559) compared to skin (R¼0.315). GI his-
tologic grade was lower than clinical grade in 64% of GVHD
episodes, the same in 15%, and higher in 21% of occurrences.
In contrast, skin histologic grade was lower than clinical
grade in only 4% of GVHD episodes, the same in 17% and
higher in 79%. Overall histologic grade, independent of tissue
site, and overall clinical grade were both signiﬁcantly asso-
ciated with day 28-treatment response. 71% (n¼70) of pa-
tients with histologic grade 1 GVHD had a complete response
(CR) to therapy; whereas only 6% (n¼1) with histologic grade
4 GVHD achieved a CR. In univariable analysis, worst GVHD
by histologic grade was predictive of non-relapse (HR 1.67,
95% CI 1.30-2.14, p<0.001) and overall mortality (HR 1.40,
95% CI 1.15-1.70, p<0.001). Similarly, overall clinical grade
was predictive of non-relapse (HR 1.41, 95% CI 1.02-1.93,
p¼0.036) and overall mortality (HR 1.60, 95% CI 1.29-1.99,
p<0.001). In multivariable analysis, overall clinical grade
remained the strongest predictor of non-relapse (HR 1.41,
95% CI 1.02-1.94, p¼0.037) and overall mortality (HR 1.65,
95% CI 1.32-2.06, p<0.001), while histologic grade became
non-signiﬁcant. In conclusion, histologic GVHD grade has
some correlation with clinical grading and treatment
response, and may play a role in further supporting the
severity of GVHD, particularly in speciﬁc tissues. Overall
clinical grade, however, remains the strongest predictor of
mortality post-transplant.497
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Introduction: NIH Consensus criteria for diagnosis of
chronic GVHD (cGVHD) have been examined in several
retrospective studies evaluating cGVHD and its comparison
to other GVHD syndromes. There is less data regarding late
aGVHD with onset beyond 100 days after HCT. We evaluated
a cohort of allogeneic HCT recipients from 2007 to 2012 who
developed persistent, recurrent or denovo late aGVHD.
Patients and Methods: 75 patients (median age 50.7 years)
were classiﬁed as late aGVHD. Donors were HLA-identical
sibling in 41.3%, UCB in 45.3%, URD in 13.3%. 46.7% recipients
